GELS Gelteq Ltd

BEARISH Impact: 7/10 6-K
Horizon weeks Filed Jun 2, 2026 Processed 10d 12h ago SEC 0001213900-26-064152
Notable filing: 6-K
Latest settled — T+1d
GELS ▲ +5.76% at T+1d
SHORT call ✗ call lost -5.76% · α vs SPY -5.36% · entry $0.4860 → $0.5140
Next anchor: T+5d due 4d ago
Currently $0.9900 · -103.70% from $0.4860 entry (call sign-flipped)
Entry anchored
Jun 2, 2026
via day open
T+1d
+5.76%
call -5.76% · α -5.36%
$0.5140
settled 10d ago
T+5d
call — · α —
due 4d ago
T+20d
call — · α —
in 18d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Gelteq is holding a special shareholder meeting on June 19, 2026, to seek approval under Nasdaq Listing Rule 5635(d) for issuing shares upon conversion of convertible notes entered into on May 7, 2026. The notes, issued to an unrelated institutional investor, have a conversion price floor of US$0.50 per share and could result in the issuance of up to approximately 8.9 million shares (illustrative maximum), representing potentially massive dilution relative to the company's $5M market cap. Failure to pass the resolution may prevent the second closing of the notes, threatening the company's access to this financing.

Actionable Insight

The vote on June 19 is a binary catalyst: passage unlocks potentially massive dilution from the convertible notes, while failure may cut off a critical financing source for a micro-cap with no disclosed revenue. Monitor proxy voting trends and any pre-meeting announcements. If the resolution passes, expect significant selling pressure from dilution overhang; if it fails, the stock may rally on relief but face liquidity risk.

Key Facts

  • Special meeting scheduled for June 19, 2026, to vote on Resolution 1: approval of share issuance upon conversion of convertible notes exceeding 19.99% of outstanding shares.
  • Convertible notes entered into on May 7, 2026, with an unrelated institutional investor; proceeds intended for commercialization, clinical trials, and working capital.
  • Illustrative maximum of approximately 8,908,548 shares issuable at a floor conversion price of US$0.50 per share, though actual number depends on conversion terms and accrued amounts.
  • Noteholder is contractually capped at 9.99% beneficial ownership, but dilution to existing shareholders could be material and occur progressively.
  • If Resolution 1 fails, the company may be unable to proceed with the second closing of the notes.
  • Market cap is approximately $5M, making the potential dilution from up to 8.9M shares extremely significant relative to current share count.

Financial Impact

Up to approximately 8,908,548 shares could be issued at a floor price of US$0.50 per share, implying potential dilution of several hundred percent relative to current outstanding shares (market cap ~$5M). Exact dilution depends on conversion mechanics and accrued amounts.

dilutionshare countworking capital

Risk Factors

  • Massive dilution to existing shareholders if the resolution passes and notes convert at low prices.
  • Failure to pass resolution could jeopardize the second closing of the notes, leaving the company without committed financing.
  • Conversion mechanics include discounts, valuation caps, and formulas that could result in even greater dilution than the illustrative maximum.
  • The company has a $5M market cap and no disclosed revenue, making it highly sensitive to capital structure changes.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-064152
Document: ea0293277-6k_gelteq.htm0001213900-26-064152
Document: 0001213900-26-064152-index-headers.html0001213900-26-064152
Document: 0001213900-26-064152-index.html0001213900-26-064152
Document: 0001213900-26-064152.txt0001213900-26-064152
2 reports for GELS
Performance horizon
Filters
Rows
Reports for GELS — sortable, filterable
Type Now
Jun 12, 2026
today
Press Release
NEUTRAL ★ 4/10
$0.9201 awaiting T+1awaiting T+1$0.9900 (+7.60%)
Jun 2, 2026
10d ago
6-K
BEARISH ★ 7/10
$0.4860 $0.5140▼ −5.76%▼ −5.36%$0.9900 (−103.70%)
Showing 2 of 2

US Market Status

Market Closed — Opens Mon (53h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access